Mr. Jia Xiaojia, CEO and co-founder of Eieling Technology Limited, announced the completion of Pre-A round of financing, with investors from ultrasound industry funds and Hong Kong background funds, and the financing amount reached tens of millions of Hong Kong dollars. This fully proves the high recognition of the capital market and shareholders for the company’s technical strength and development prospects, and creates favorable conditions for the market layout and iterative upgrade of products such as the Liverscan®️ series, FattaLab®️ series, and EieBot series.
About Eieling Technology
In 2018, Eieling Technology was registered and established in Hong Kong Science Park. As a research and development transformation enterprise of the Hong Kong Polytechnic University, it focuses on providing accurate and reliable intelligent liver health diagnosis solutions to global healthcare providers.
Its flagship product, Liverscan®, is equipped with THE WORLD’S EXCLUSIVE patented technology for real-time B-mode ultrasound-guided transient elastography, which creatively integrates the two technologies of Ultrasonic real-time imaging guide B and transient elastic imaging (TE) detection into a wireless composite probe. It can not only improve the speed and efficiency of clinical detection and reduce the difficulty of medical work but also optimize the life cycle cost of medical device products.
Eieling Technology always adheres to the development strategy of original research and innovation, continues to delve into the cutting-edge technology of liver health diagnosis, plans product development strategy, and launches Liverscan®️, FattaLab®️, EieBot product line, and chronic liver disease big data management platform. It not only enhances the company’s cutting-edge technology innovation capabilities but also injects new momentum into the development of liver health diagnosis technology.
On February 17 this year, witnessed by the mayor of Nanjing, Eieling Technology and the Management Committee of Nanjing Jiangning High-tech Industrial Development Zone jointly signed the Eieling Technology Super Factory Project Investment Framework Agreement. Eieling Technology’s first super factory in the world was officially established in Jiangning District, Nanjing, opening a new chapter of development.
Subsequently, Mr. Jia Xiaojia, CEO and co-founder of Eieling Technology Limited, announced important personnel appointments, which marked the further optimization and upgrading of the company’s organizational structure, laying a solid foundation for the company’s current business development and continued growth in the future market.
Eieling Technology’s first global super factory- Nanjing subsidiary General Manager Appointment:
Zhao Peng, graduated from Shanghai Tongji University with a major in German in 2001, went to Germany for further studies and successfully founded a business there. After returning to China in 2005, he successively obtained MBA degrees from Guanghua School of Management of Peking University and Nanjing University. He was the general manager of Nanjing Jiuzhu Technology Industry Co., Ltd., Jiangsu Chegong Technology Co., Ltd., and the executive vice president of Jiangsu Huize Information Technology Co., Ltd., with more than 20 years of experience in the operation and management of manufacturing enterprises.
Appointment of National Channel Development Director of Eieling Technology:
Yang Ming, who has held senior management positions at Novartis Pharmaceuticals Group and GE Healthcare, has been deeply involved in the pharmaceutical and medical device fields for more than 20 years and has rich industry experience, especially in direct sales, commercial distribution, channel management, and team management.
Eieling Technology makes full use of its regional advantages, optimizes resource allocation, and promotes various key tasks. At present, the company is actively preparing for the establishment of a subsidiary in the United States, the headquarters of the Western Hemisphere, to serve the North American and South American markets; and Hong Kong, China, as the headquarters of the Eastern Hemisphere, relies on the vast market resources of the motherland to provide services to countries along the Belt and Road.
Eieling Technology is steadily moving towards a stronger and more stable development path. In the future, it will continue to take root, bring more cutting-edge concepts, high-quality projects and technologies to the public, continue to empower the development and technological innovation in the field of liver disease health management, and contribute more to the cause of human health.
Embrace change and lead the trend of innovation
Riding on the spring breeze of the new era and new journey, Eieling Technology will continue to enhance its original innovation and key core technology research capabilities, accelerate the development of more non-invasive liver testing products with national leading levels, and provide patients with more efficient, safer, and more convenient liver health diagnosis solutions.
We sincerely thank every investor for their trust and support. We will continue to unswervingly strengthen product research and development, accelerate the transformation of scientific research results, and build a new highland of scientific and technological innovation.
We welcome the attention and support from more investment institutions and market partners in the industry!